CrossrefInfokarte
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses
Journal of Gynecologic Oncology · 2026 · 37 (3)
DOI: 10.3802/jgo.2026.37.e65 ↗Abstract
Kein Abstract verfügbar.
EUVIMED